tiprankstipranks
Trending News
More News >
Inovio Pharmaceuticals (INO)
NASDAQ:INO

Inovio Pharmaceuticals (INO) Stock Statistics & Valuation Metrics

Compare
5,827 Followers

Total Valuation

Inovio Pharmaceuticals has a market cap or net worth of $77.75M. The enterprise value is -$28.57B.
Market Cap$77.75M
Enterprise Value-$28.57B

Share Statistics

Inovio Pharmaceuticals has 36,674,435 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding36,674,435
Owned by Insiders0.73%
Owned by Institutions10.93%

Financial Efficiency

Inovio Pharmaceuticals’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.14%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)-0.95
Return on Invested Capital (ROIC)-0.14%
Return on Capital Employed (ROCE)-1.44
Revenue Per Employee1.63K
Profits Per Employee-800.40K
Employee Count134
Asset Turnover<0.01
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Inovio Pharmaceuticals is -0.46. Inovio Pharmaceuticals’s PEG ratio is -0.02.
PE Ratio-0.46
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio-0.02

Income Statement

In the last 12 months, Inovio Pharmaceuticals had revenue of 217.76K and earned -107.25M in profits. Earnings per share was -3.95.
Revenue217.76K
Gross Profit-2.91M
Operating Income-112.40M
Pretax Income-107.25B
Net Income-107.25M
EBITDA-103.95M
Earnings Per Share (EPS)-3.95

Cash Flow

In the last 12 months, operating cash flow was -111.28B and capital expenditures 35.58K, giving a free cash flow of -111.28B billion.
Operating Cash Flow-111.28B
Free Cash Flow-111.28B
Free Cash Flow per Share-3.03K

Dividends & Yields

Inovio Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.69
52-Week Price Change-78.34%
50-Day Moving Average1.84
200-Day Moving Average3.48
Relative Strength Index (RSI)61.57
Average Volume (3m)517.18K

Important Dates

Inovio Pharmaceuticals upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date

Financial Position

Inovio Pharmaceuticals as a current ratio of 2.77, with Debt / Equity ratio of 21.99%
Current Ratio2.77
Quick Ratio2.77
Debt to Market Cap0.00
Net Debt to EBITDA519.00
Interest Coverage Ratio-632.05

Taxes

In the past 12 months, Inovio Pharmaceuticals has paid -107.15B in taxes.
Income Tax-107.15B
Effective Tax Rate1.00

Enterprise Valuation

Inovio Pharmaceuticals EV to EBITDA ratio is 518.52, with an EV/FCF ratio of 515.46.
EV to Sales-247.52K
EV to EBITDA518.52
EV to Free Cash Flow515.46
EV to Operating Cash Flow517.87

Balance Sheet

Inovio Pharmaceuticals has $68.36B in cash and marketable securities with $11.27B in debt, giving a net cash position of -$57.09B billion.
Cash & Marketable Securities$68.36B
Total Debt$11.27B
Net Cash-$57.09B
Net Cash Per Share-$1.56K
Tangible Book Value Per Share$2.52

Margins

Gross margin is -636.81%, with operating margin of -51616.91%, and net profit margin of -49254.27%.
Gross Margin-636.81%
Operating Margin-51616.91%
Pretax Margin-49254269.00%
Net Profit Margin-49254.27%
EBITDA Margin-47735.19%
EBIT Margin-49172.60%

Analyst Forecast

The average price target for Inovio Pharmaceuticals is $8.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.25
Price Target Upside280.18% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast-60.52%
EPS Growth Forecast42.41%

Scores

Smart Score2
AI Score51
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis